Georgia 2025-2026 Regular Session

Georgia House Bill HB717

Introduced
3/3/25  
Report Pass
3/6/25  
Report Pass
2/4/26  
Engrossed
3/6/26  
Refer
3/9/26  
Report Pass
3/19/26  

Caption

Medical Practice Act; regulation of the administration of psychedelic-assisted treatment and therapy; provide

Impact

If enacted, HB 717 will have significant implications on state laws governing medical practices related to psychiatric and psychological treatment. Clinics that offer psychedelic-assisted therapies will need to be licensed by a state board, which will also oversee the establishment of standards for safe practice. These regulations must be implemented by December 2026, presenting a structured approach to integrating these therapies into Georgia's healthcare system, which may lead to refinement in practices related to mental health treatment.

Summary

House Bill 717 aims to amend the Medical Practice Act in Georgia by establishing regulations surrounding psychedelic-assisted treatment and therapy. This legislation will provide a framework for defining, administering, and managing treatment involving psychedelic substances. The bill sets forth specific standards for clinics, including requirements for proper equipment, clinician competency, record-keeping, and emergency protocols, all aimed at enhancing patient safety and ensuring effective treatment delivery.

Sentiment

The overall sentiment surrounding HB 717 appears to be cautiously optimistic among healthcare professionals who see the potential benefits of psychedelic therapy for mental health conditions. However, there are underlying concerns regarding the regulatory burden on clinics and the scope of allowable treatments. Some stakeholders may see the regulations as necessary safeguards, while others may view them as excessive, potentially limiting access to alternative therapies.

Contention

Key points of contention surrounding HB 717 include the complexities of integrating psychedelic-assisted treatments into existing medical frameworks and the balance between sufficient regulation and enabling access to what some view as innovative treatment options. Additionally, there are potential disagreements on ensuring the right qualifications for practitioners and addressing the qualifications for clinic ownership, which may lead to further debates within the legislative process.

Companion Bills

No companion bills found.

Previously Filed As

GA SB43

Provides relative to psychedelic-assisted therapy. (8/1/26) (REF INCREASE GF EX See Note)

GA HB4014

Relating to a study on the use of psychedelic therapies in the treatment of certain conditions.

GA SB3005

Relating to a study on the use of psychedelic therapies in the treatment of certain conditions.

GA SB00191

An Act Concerning The Psychedelic-assisted Therapy Pilot Program.

GA SJR10

Urges Congress to take certain actions relating to the therapeutic use of certain psychedelic compounds. (BDR R-801)

GA H4200

Authorizing a pilot for the use of psychedelics in licensed treatment facilities

GA S1400

Authorizing a pilot for the use of psychedelics in licensed treatment facilities

GA HB1275

Medical practice; ensure that stem cell therapies are used to advance medical treatments and improve patient outcomes in an ethical manner that does not involve stem cells derived from aborted fetuses

GA SB00855

An Act Concerning Funding For The Psychedelic-assisted Therapy Pilot Program.

GA SB1682

Modifies provisions relating to alternative therapies and treatments, including psilocybin

Similar Bills

MD SB336

Task Force on Responsible Use of Natural Psychedelic Substances - Extension and Membership

MD HB427

Task Force on Responsible Use of Natural Psychedelic Substances - Extension and Membership

NV SJR10

Urges Congress to take certain actions relating to the therapeutic use of certain psychedelic compounds. (BDR R-801)

TX HB4014

Relating to a study on the use of psychedelic therapies in the treatment of certain conditions.

AZ SB1555

Approved medication; rescheduling; controlled substance

TX SB3005

Relating to a study on the use of psychedelic therapies in the treatment of certain conditions.

NJ A1526

Establishes Psilocybin Behavioral Health Access and Therapy Pilot Program; appropriates $6 million.

MA H4200

Authorizing a pilot for the use of psychedelics in licensed treatment facilities